

CITATION REPORT

List of articles citing

Review of utility values for economic modeling in type 2 diabetes

DOI: 10.1016/j.jval.2014.03.003
Value in Health, 2014, 17, 462-70.

Source: <https://exaly.com/paper-pdf/59740509/citation-report.pdf>

Version: 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
147	Validation of the IMS CORE Diabetes Model. <i>Value in Health</i> , 2014 , 17, 714-24	3.3	127
146	Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK. 2015 , 109, 95-103		3
145	Health state utility values for diabetic retinopathy: protocol for a systematic review and meta-analysis. 2015 , 4, 15		7
144	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. 2016 , 34, 953-66		20
143	Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study. <i>Value in Health</i> , 2016 , 19, 36-41	3.3	55
142	Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands. 2016 , 19, 742-9		13
141	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. 2016 , 61, 2108-17		44
140	Cost-Effectiveness of Sensor-Augmented Pump Therapy with Low Glucose Suspend Versus Standard Insulin Pump Therapy in Two Different Patient Populations with Type 1 Diabetes in France. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 75-84	8.1	28
139	Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective. 2016 , 19, 236-42		30
138	An equivalence study: Are patient-completed and telephone interview equivalent modes of administration for the EuroQol survey?. 2017 , 15, 18		17
137	Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark. 2017 , 128, 6-14		14
136	Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK. <i>Diabetes Therapy</i> , 2017 , 8, 513-530	3.6	15
135	The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥ 30 kg/m. 2017 , 20, 443-452		11
134	Cost-Effectiveness Analysis of Sensor-Augmented Insulin Pump Therapy with Automated Insulin Suspension Versus Standard Insulin Pump Therapy in Patients with Type 1 Diabetes in Sweden. <i>Diabetes Therapy</i> , 2017 , 8, 1015-1030	3.6	10
133	Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective. 2017 , 20, 1128-1135		14
132	Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. 2017 , 15, 125		13
131	A systematic literature review of health state utility values in head and neck cancer. 2017 , 15, 174		24

130	Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA _{1c} , weight and hypoglycaemic event incidence. <i>Diabetic Medicine</i> , 2018 , 35, 557-566	3.5	10
129	Utility values for childhood obesity interventions: a systematic review and meta-analysis of the evidence for use in economic evaluation. 2018 , 19, 905-916		15
128	The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan. 2018 , 21, 488-496		5
127	Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy. 2018 , 28, 707-715		7
126	Cost-effectiveness of prevention and management of diabetic foot ulcer and amputation in a health resource-limited setting. <i>Journal of Diabetes</i> , 2018 , 10, 320-327	3.8	21
125	A Systematic Review and Meta-analysis of Childhood Health Utilities. <i>Medical Decision Making</i> , 2018 , 38, 277-305	2.5	32
124	Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. 2018 , 36, 349-358		4
123	The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. <i>Diabetes Therapy</i> , 2018 , 9, 13-25	3.6	8
122	Cost-effectiveness of telemonitoring screening for diabetic foot ulcer: a mathematical model. 2018 , 6, E486-E494		5
121	Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. 2018 , 65, 380-386		
120	Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. 2018 , 65, 380-386		6
119	Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis. 2018 , 168, 170-178		19
118	A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes. 2017 , 2, 20		1
117	A Practical Guide to Conducting a Systematic Review and Meta-analysis of Health State Utility Values. 2018 , 36, 1043-1061		15
116	Cost-Effectiveness Analysis of Empagliflozin in Comparison to Sitagliptin and Saxagliptin Based on Cardiovascular Outcome Trials in Patients with Type 2 Diabetes and Established Cardiovascular Disease. <i>Diabetes Therapy</i> , 2019 , 10, 2153-2167	3.6	12
115	Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy. 2019 , 11, 605-614		5
114	Meta-Analysis and Cost-Effectiveness Analysis of Insulin Glargine 100 U/mL Versus Insulin Degludec for the Treatment of Type 2 Diabetes in China. <i>Diabetes Therapy</i> , 2019 , 10, 1969-1984	3.6	3
113	Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 727-735	8.1	2

112	Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security. 2019 , 17, 19		3
111	Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi. <i>Diabetes Therapy</i> , 2019 , 10, 493-508	3.6	5
110	The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia. <i>Advances in Therapy</i> , 2019 , 36, 2034-2051	4.1	5
109	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019 , 10, 1297-1317	3.6	14
108	Cost-Effectiveness Analysis of the MiniMed 670G Hybrid Closed-Loop System Versus Continuous Subcutaneous Insulin Infusion for Treatment of Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2019 , 21, 110-118	8.1	26
107	Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. <i>Diabetes Therapy</i> , 2019 , 10, 563-574	3.6	3
106	Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. 2019 , 7, e000705		7
105	Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia. <i>Diabetes Therapy</i> , 2019 , 10, 159-176	3.6	7
104	Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1010-1017	6.7	4
103	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 611-621	6.7	21
102	Assessing the cost-effectiveness of a once-weekly GLP-1 analogue versus an SGLT-2 inhibitor in the Spanish setting: Once-weekly semaglutide versus empagliflozin. 2020 , 23, 193-203		10
101	Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. 2021 , 7, 529-538		2
100	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. 2020 , 22, 2147-2156		41
99	Quality of Life and Utility Values for Cost-Effectiveness Modeling in Japanese Patients with Type 2 Diabetes. <i>Diabetes Therapy</i> , 2020 , 11, 2931-2943	3.6	1
98	Evaluation of the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Dulaglutide and Sitagliptin in the Spanish Setting. <i>Advances in Therapy</i> , 2020 , 37, 4427-4445	4.1	3
97	LIVING WITH COVID-19: BALANCING COSTS AGAINST BENEFITS IN THE FACE OF THE VIRUS. 2020 , 253, R60-R76		34
96	Economic evaluation of dapagliflozin versus metformin in Chinese patients whose diabetes is inadequately controlled with diet and exercise. 2020 , 18, 12		5
95	The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review. 2020 , 15, e0230512		36

94	Five-year cost-effectiveness analysis of the European Fans in Training (EuroFIT) physical activity intervention for men versus no intervention. 2020 , 17, 30		2
93	Cost-effectiveness of empagliflozin compared with liraglutide based on cardiovascular outcome trials in Type II diabetes. 2020 , 9, 781-794		6
92	Long-term Cost-Effectiveness of Dexcom G6 Real-time Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Patients With Type 1 Diabetes in the U.K. <i>Diabetes Care</i> , 2020 , 43, 2411-2417	14.6	11
91	Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications. <i>European Journal of Health Economics</i> , 2020 , 21, 729-743	3.6	6
90	Cost-benefit Analysis in Health Care: The Case of Bariatric Surgery Compared With Diet. 2020 , 42, 60-75.e7		1
89	Automated Tool for Health Utility Assessments: The Gambler II. 2020 , 5, 2381468320914307		2
88	Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type2 Diabetes in the UK. <i>Advances in Therapy</i> , 2020 , 37, 2427-2441	4.1	6
87	"Stay at Home, Protect the National Health Service, Save Lives": A cost benefit analysis of the lockdown in the United Kingdom. 2021 , 75, e13674		27
86	Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. <i>Diabetes Therapy</i> , 2021 , 12, 235-246	3.6	3
85	Patient Health Utility Equations for a Type 2 Diabetes Model. <i>Diabetes Care</i> , 2021 , 44, 381-389	14.6	2
84	Determinants and impact of physical impairment in patient-reported outcomes among older patients with type 2 diabetes mellitus in Japan. 2021 , 37, 393-402		
83	Health utility of type 2 diabetes patients using basal insulin in China: results from the BEYOND II study. 2021 , 58, 329-339		2
82	Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1mg Versus Empagliflozin 25mg for Treatment of Patients with Type2 Diabetes in the UK Setting. <i>Diabetes Therapy</i> , 2021 , 12, 537-555	3.6	5
81	Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany. <i>Value in Health</i> , 2021 , 24, 274-280	3.3	2
80	Valuing health states of people with type2 diabetes: Analyses of the nationwide representative linked databases. 2021 , 12, 1749-1758		0
79	The Cost-Effectiveness of Empagliflozin Versus Liraglutide Treatment in People with Type2 Diabetes and Established Cardiovascular Disease. <i>Diabetes Therapy</i> , 2021 , 12, 1523-1534	3.6	3
78	The Perspectives of Patients with Chronic Diseases and Their Caregivers on Self-Management Interventions: A Scoping Review of Reviews. 2021 , 14, 719-740		3
77	The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials. 2021 , 175, 108759		4

76	Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification. 2021 , 21, 105		0
75	Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis. <i>Value in Health</i> , 2021 , 24, 1059-1067	3.3	1
74	Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey. 2021 , 14, 929-941		2
73	Economic Evaluation of Sucrose Octasulfate Dressing for Treatment of Diabetic Foot Ulcers in Patients with Type 2 Diabetes.. 2021 ,		1
72	Evaluation of the Long-Term Cost-Effectiveness of the Dexcom G6 Continuous Glucose Monitor versus Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in Canada. 2021 , 13, 717-725		1
71	Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China. 2021 , 19, 46		1
70	Pharmacy-based screening to detect persons at elevated risk of type 2 diabetes: a cost-utility analysis. <i>BMC Health Services Research</i> , 2021 , 21, 916	2.9	0
69	Review and estimation of disutility for joint health states of severe and nonsevere hypoglycemic events in diabetes. 2021 , 10, 961-974		0
68	Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK. 2021 , 24, 883-890		2
67	The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. 2016 , 11, e0162441		8
66	Cost-effectiveness Analysis of a Flash Glucose Monitoring System for Patients with Type 1 Diabetes Receiving Intensive Insulin Treatment in Sweden. 2018 , 14, 73-79		15
65	Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis. 2019 , 21, e15814		12
64	Integrated sensor-augmented pump therapy systems [the MiniMed [®] Paradigm [®] Veo system and the Vibe [®] and G4 [®] PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation. 2016 , 20, v-xxxi, 1-251		44
63	A randomised trial of the effect and cost-effectiveness of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with screen-detected type 2 diabetes: the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION-T2). 2014 , 22, 1-10		11
62	A cluster randomised trial, cost-effectiveness analysis and psychosocial evaluation of insulin pump therapy compared with multiple injections during flexible intensive insulin therapy for type 1 diabetes: the REPOSE Trial. 2017 , 21, 1-278		31
61	Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model. 2018 , 6, 84-95		4
60	Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2021 , 1-9	2.2	0
59	Type 2 Diabetes-Related Health Economic Impact Associated with Increased Whole Grains Consumption among Adults in Finland. 2021 , 13,		3

58	Cluster randomised controlled trial and economic and process evaluation to determine the effectiveness and cost-effectiveness of a novel intervention [Healthy Lifestyles Programme (HeLP)] to prevent obesity in school children. 2018 , 6, 1-204		2
57	Estimating the Impact of Novel Digital Therapeutics in Type 2 Diabetes and Hypertension: Health Economic Analysis (Preprint).		0
56	Cost-Effectiveness of iGlarLixi Versus iDegLira in Type 2 Diabetes Mellitus Inadequately Controlled by GLP-1 Receptor Agonists and Oral Antihyperglycemic Therapy. <i>Diabetes Therapy</i> , 2021 , 12, 3231-3241	3.6	1
55	Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK. <i>Diabetes Therapy</i> , 2021 , 12, 3217-3230	3.6	0
54	Lifetime Cost-effectiveness of Oral Semaglutide Versus Dulaglutide and Liraglutide in Patients With Type 2 Diabetes Inadequately Controlled With Oral Antidiabetics. 2021 ,		1
53	Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. 2021 ,		0
52	Cost-effectiveness of the Da Qing diabetes prevention program: A modelling study. 2020 , 15, e0242962		1
51	Skin Substitutes for Adults With Diabetic Foot Ulcers and Venous Leg Ulcers: A Health Technology Assessment. 2021 , 21, 1-165		1
50	The cost-effectiveness of oral semaglutide versus empagliflozin in Type 2 diabetes in Denmark. 2022 , 11, 29-37		2
49	Cost-effectiveness of professional-mode flash glucose monitoring in general practice among adults with type 2 diabetes: Evidence from the GP-OSMOTIC trial. <i>Diabetic Medicine</i> , 2021 , e14747	3.5	0
48	Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting.. 2022 , 1		2
47	A cost-benefit analysis of COVID-19 lockdowns in Australia.. <i>Monash Bioethics Review</i> , 2022 , 1	2.3	1
46	The impact of loneliness and social isolation on health state utility values: a systematic literature review.. <i>Quality of Life Research</i> , 2022 , 1	3.7	0
45	Quality-Adjusted Life-Years Lost Due to COVID-19 Mortality: Methods and Application for The Netherlands.. <i>Value in Health</i> , 2022 , 25, 731-735	3.3	1
44	Erratum.. <i>Journal of Wound Care</i> , 2022 , 31, S31	2.2	
43	Cost-effectiveness of dehydrated human amnion/chorion membrane allografts in lower extremity diabetic ulcer treatment.. <i>Journal of Wound Care</i> , 2022 , 31, S10-S31	2.2	3
42	The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark.. <i>Diabetes Therapy</i> , 2022 , 13, 489	3.6	0
41	The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.. <i>Diabetology and Metabolic Syndrome</i> , 2022 , 14, 32	5.6	0

40	Costs of Public Health Screening of Children for Presymptomatic Type 1 Diabetes in Bavaria, Germany.. <i>Diabetes Care</i> , 2022 ,	14.6	1
39	Cost-Effectiveness of Hybrid Closed Loop Insulin Pumps Versus Multiple Daily Injections Plus Intermittently Scanned Glucose Monitoring in People With Type 1 Diabetes in The Netherlands.. <i>Advances in Therapy</i> , 2022 , 39, 1844	4.1	0
38	Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study.. <i>BMC Health Services Research</i> , 2022 , 22, 217	2.9	0
37	Long-term cost-effectiveness of Dexcom G6 real-time continuous glucose monitoring system in people with type 1 diabetes IN Australia.. <i>Diabetic Medicine</i> , 2022 , e14831	3.5	0
36	The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study.. <i>JMIR Research Protocols</i> , 2022 , 11, e35461	2	0
35	Cost-effectiveness of multicomponent interventions in type 2 diabetes mellitus in a cluster randomised controlled trial: the INDICA study.. <i>BMJ Open</i> , 2022 , 12, e058049	3	
34	Cost-effectiveness analysis of an Advanced Hybrid Closed Loop insulin delivery system in people with type 1 diabetes in Greece.. <i>Diabetes Technology and Therapeutics</i> , 2021 ,	8.1	0
33	Decrements in health-related quality of life associated with adverse events in people with diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 ,	6.7	1
32	Exploring Structural Uncertainty and Impact of Health State Utility Values on Lifetime Outcomes in Diabetes Economic Simulation Models: Findings from the Ninth Mount Hood Diabetes Quality-of-Life Challenge.. <i>Medical Decision Making</i> , 2021 , 272989X211065479	2.5	
31	The Impact of Hypoglycemia on Productivity Loss and Utility in Patients With Type 2 Diabetes Treated With Insulin in Real-world Canadian Practice: Protocol for a Prospective Study (Preprint).		
30	The Cost-Effectiveness Analysis of Self-Efficacy-Focused Structured Education Program for Patients With Type 2 Diabetes Mellitus in Mainland China Setting.. <i>Frontiers in Public Health</i> , 2021 , 9, 767123	6	
29	Health Utilities in Patients with Type 2 Diabetes in Taiwan.. <i>Healthcare (Switzerland)</i> , 2021 , 9,	3.4	0
28	Early Education and Adult Health: Age 37 Impacts and Economic Benefits of the Child-Parent Center Preschool Program. <i>Journal of Benefit-Cost Analysis</i> , 2022 , 13, 57-90	2.6	1
27	Quality of Life Assessment for Tonsillar Infections and Their Treatment. <i>Medicina (Lithuania)</i> , 2022 , 58, 589	3.1	
26	Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK.. <i>Diabetes Therapy</i> , 2022 ,	3.6	0
25	The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.. <i>Advances in Therapy</i> , 2022 , 1	4.1	
24	Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma.. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2022 ,	2.2	0
23	Cost-effectiveness analysis of continuous subcutaneous insulin infusion versus multiple daily insulin for treatment of children with Type 1 diabetes. <i>Postgraduate Medicine</i> ,	3.7	0

22	Hospital costs associated with adverse events in people with diabetes in the UK. <i>Diabetes, Obesity and Metabolism</i> ,	6.7	o
21	Health utilities in Chinese patients with coronary heart disease and impaired glucose tolerance (ACE): A longitudinal analysis of a randomized, double-blind, placebo-controlled trial. <i>Journal of Diabetes</i> , 2022 , 14, 455-464	3.8	o
20	Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations. <i>European Journal of Health Economics</i> ,	3.6	o
19	Long-Term Cost-Effectiveness Analysis of Once-Weekly Semaglutide versus Dulaglutide in Patients with Type 2 Diabetes with Inadequate Glycemic Control in China.		1
18	The long-term cost-effectiveness of once-weekly semaglutide 1mg vs. dulaglutide 3mg and 4.5mg in the UK.		o
17	Economic evaluation of using polygenic risk score to guide risk screening and interventions for the prevention of type 2 diabetes in individuals with high overall baseline risk. 13,		o
16	First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.		4
15	Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK.		1
14	Cost-effectiveness of insulin degludec/insulin aspart versus biphasic insulin aspart in Chinese population with type 2 diabetes. 10,		o
13	Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK : A long-term cost-effectiveness analysis based on SUSTAIN 11.		1
12	Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease. CJN.03790322		o
11	Health State Utility Values of Type 2 Diabetes Mellitus and Related Complications: A Systematic Review and Meta-Analysis. 2023 , 34, 14-22		o
10	Model-based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease.		o
9	Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs, and mortality.		o
8	Projecting the incidence and costs of major cardiovascular and kidney complications of type 2 diabetes with widespread SGLT2i and GLP-1 RA use: a cost-effectiveness analysis.		o
7	Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China.		o
6	Cost-effectiveness of immediate initiation of dapagliflozin in patients with a history of heart failure.		1
5	Cost-effectiveness of Simple Insulin Infusion Devices Compared to Multiple Daily Injections in Uncontrolled Type 2 Diabetics in the United States Based on a Simulation Model. 84-95		o

- 4 Targeting Diabetes Prevention to More Disadvantaged Groups Improves Cost-Effectiveness: Implications of Inequality in Type 2 Diabetes From Theoretical Interventions. **2023**,
- 3 Model-based economic evaluation of the effectiveness of "ypos"tan strike twice" a leaflet-based ambulance clinician referral intervention to prevent recurrent hypoglycaemia. **2023**, 18, e0282987
- 2 Long-term cost-effectiveness of implementing a lifestyle intervention during pregnancy to reduce the incidence of gestational diabetes and type 2 diabetes.
- 1 Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide 1mg Versus Liraglutide 1.8 mg: A Health Economic Analysis in the UK. **2023**, 14, 1005-1021